Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
Vietti Violi N, Lewis S, Liao J, Hulkower M, Hernandez-Meza G, Smith K, Babb JS, Chin X, Song J, Said D, Kihira S, Sirlin CB, Reeder SB, Bashir MR, Fowler KF, Ferket BS, Sigel K, Taouli B.
Eur Radiol. 2020 Nov;30(11):6003-6013.

Ferumoxytol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment.
Gallo CJR, Mammarappallil JG, Johnson DY, Chalian H, Ronald J, Bashir MR, Kim CY.
Radiol Cardiothorac Imaging. 2020 Nov 19;2(6):e200339.

Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI.
Nguyen KL, Yoshida T, Kathuria-Prakash N, Zaki IH, Varallyay CG, Semple SI, Saouaf R, Rigsby CK, Stoumpos S, Whitehead KK, Griffin LM, Saloner D, Hope MD, Prince MR, Fogel MA, Schiebler ML, Roditi GH, Radjenovic A, Newby DE, Neuwelt EA, Bashir MR, Hu P, Finn JP.
Radiology. 2019 Dec;293(3):554-564.

LI-RADS: Diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10-19mm with arterial phase hyperenhancement.
Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzales F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D.
AJR Am J Roentgenol. 2019 Aug;213(2):W57-W65.

Comparison of visualization rates of LI-RADS version 2014 major features with IV gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma.
Allen BC, Ho LM, Jaffe TJ, Miller CM, Mazurowski MA, Bashir MR.
ARJ Am J Roentgenol. 2018 Jun;210(6):1266-1272.

Respiratory Motion Artifacts During Arterial Phase Imaging with Gardoxetic Acid: Can the Injection Protocol Minimize this Drawback?
Polanec SH, Bickel H, Baltzer PA, Thurner P, Gittler F, Hodge JC, Bashir MR, Ba- Ssalameh A.
J Magn Reson Imaging. 2017 Oct;46(4):1107-1114.

Gadolinium-based contrast agents: A comprehensive risk assessment.
Fraum T, Ludwig D, Bashir MR, Fowler KJ.
J Magn Reson Imaging. 2017 Aug;46(2):338-353.

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.
Toth GB, Csanad GV, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, Dosa E, Finn JP, Gahramanov S, Harisinghani M, Macdougall I, Neuwelt A, Vasanawala SS, Ambady P, Barajas R, Cetas JS, Ciporen J, DeLoughery TJ, Doolittle ND, Fu R, Grinstead J, Guimaraes AR, Hamilton BE, Li X, McConnell HL, Muldoon LL, Nesbit G, Netto JP, Petterson D, Rooney WD, Schwartz D, Szidonya L, Neuwelt EA.
Kidney Int. 2017 Jul;92(1):47-66.

Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis.
Fananapazir G, Bashir MR, Corwin MT, Lamba R, Vu CT, Troppman C.
J Magn Reson Imaging. 2017 Mar;45(3):779-785.

Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, VanBeers BE.
J Magn Reson Imaging. 2017 Mar;45(3):646-659.

Intravenous gadoxetate disodium administration reduces breath-holding capacity in the hepatic arterial phase – A multi-center randomized placebo-controlled trial.
McClellan TR, Motosugi U, Middleton MS, Allen BC, Jaffe TA, Miller CM, Reeder SB, Sirlin CB, Bashir MR.
Radiol. 2017 Feb;282(2):361-368.

Can combining triple-arterial phase acquisition with fluoroscopic triggering provide both optimal early and late hepatic arterial phase images during gadoxetic acid-enhanced MRI?
Sofue K, Marin D, Jaffe TA, Nelson RC, Bashir MR.
J Magn Reson Imaging. 2016 May;43(5):1073-81.

Safety and technique of ferumoxytol administration for MRI.
Vasanawala S, Nguyen KL, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir MR.
Magn Reson Med. 2016 May;75(5):2107-11.

Consensus report from the 7th international form for liver magnetic resonance imaging.
Merkle EM, Zech CJ, Bartolozzi C, Bashir MR, Ba-Ssalamah A, Huppertz A, Lee JM, Ricke J, Sakamoto M, Sirlin CB, Ye SL, Zeng M.
Eur Radiol. 2016 Mar;26(3):674-82.

Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR, Bhatti L, Marin D, Nelson RC.
J Magn Reson Imaging. 2015 Apr;41(4):884-98.

Respiratory motion artifact affecting hepatic arterial imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium.
Bashir MR, Castelli P, Davenport MS, Larson D, Marin D, Hussein HK, Jaffe TA.
Radiology. 2015 Jan;274(1)141-8.

Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact.
Davenport MS, Bashir MR, PIetryga JA, Weber JT, Khalatbari S, Hussain HK.
Am J Roentgenol. 2014 Oct;203(4):796-802.

Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with end-stage renal diseases.
Bashir MR, Mody R, Neville A, Javan R, Seaman D, Kim CY, Gupta RT, Jaffe TA.
J Magn Reson Imaging. 2014 Jul;40(1):113-8.

Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment.
Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR.
J Vasc Interv Radiol. 2014 Jun;2(6):969-76.

Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.
Bashir MR, Breault SR, Braun R, Do RK, Nelson RC, Reeder SB.
Acad Radiol. 2014 Jun;21(6):726-32.

Impact of pre- contrast T10 relaxation times on DCE-MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value.
Heye T, Boll DT, Reiner CS, Bashir MR, Dale BM, Merkle EM.
J Magn Reson Imaging. 2014 May;39(5):1136-45.

Respiratory motion artifact affecting hepatic arterial phase hepatic arterial phase imaging with gadoxetate disodium:  examination recovery using multi-arterial phase acquisition.
PIetryga JA, Burke LMB, Marin Daniele, Jaffe TA, Bashir MR.
Radiology. 2014 May;271(2):426-34.

Gadofosveset-enhanced MR angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.
Kim CY, Heye T, Bashir MR, Gebhard TA, Merkle EM.
J Comput Assist Tomogr. 2013 Sep/Oct;37(5):732-6.

Inter- and intra-rater reproducibility of quantitative dynamic contrast enhanced MRI using TWIST perfusion data in a uterine fibroid model.
Davenport MS, Heye T, Dale BM, Horvath JJ, Breault SR, Feuerlein S, Bashir MR, Boll DT, Merkle EM.
J Magn Reson Imaging. 2013 Aug;38(2):329-35.

Renal transplant imaging using magnetic resonance angiography with a non-nephrotoxic contrast agent.
Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ.
Transplantation. 2013 Jul 15;96(1):91-6.

MR assessment of biliary ductal obstruction: Is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography?
Reiner CS, Merkle EM, Bashir MR, Walle NL, Nazeer HK, Gupta RT.
Am J Roentgenol. 2013 Jul;201(1):W49-56.

Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents – comparison of Gd-EOB-DTPA and GD-BOPTA.
Ringe KI, Boll DT, Husarik DB, Bashir MR, Gupta RT, Merkle EM.
BMC Med Imaging. 2013 Mar 18;13(1):10.

Reproducibility of dynamic contrast-enhanced MR imaging. Part II. Comparison of intra- and inter-observer variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis.
Heye T, Merkle EM, Reiner CS, Davenport MS, Horvath JJ, Feuerlein S, Brealt SR, Gall P, Bashir MR, Dale BM, Kiraly AP, Boll DT.
Radiology. 2013 Mar;266(3):812-21.

Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis using multiple computer-aided diagnosis perfusion analysis solutions.
Heye T, Davenport MS, Horvath JJ, Feuerlein S, Breault SR, Bashir MR, Merkle EM, Boll DT.
Radiology. 2013 Mar;266(3):801-11.

Iodine quantification utilizing dual-energy MDCT imaging: phantom study assessing impact of iterative reconstruction schemes and patient habitus on accuracy.
Feuerlein S, Heye T, Bashir MR, Boll DT.
Invest Radiol. 2012 Nov;47(11):656-61.

Liver MR imaging in the hepatocyte phase with Gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?
Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM.
J Magn Reson Imaging. 2012 Mar; 35(3):611-6.

Contrast-enhanced MR angiography: first pass arterial enhancement as a function of gadolinium-chelate concentration, and the saline chaser volume and injection rate.
Husarik DB, Bashir MR, Weber PW, Nichols EB, Howle LE, Merkle EM, Nelson RC.
Invest Radiol. 2012 Feb;47(2):121-7.

Rate of contrast material extravasations and allergic-like reactions: Effect of extrinsic warming of low osmolality iodinated contrast material to 37 degrees C.
Davenport MS, Lee C, Neville AM, Bashir MR, Paulson EK.
Radiology. 2012 Feb;262(2):475-84.

Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging.
Bashir MR, Merkle EM.
Eur Radiol. 2011 Feb; 21(2):29